Minerva Neurosciences (NERV) Expected to Release Quarterly Earnings on Wednesday

Minerva Neurosciences (NASDAQ:NERV) is expected to issue its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect the company to post earnings of ($0.14) per share for the quarter. Individuals can find conference call details on the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 12, 2026 at 12:30 PM ET.

Minerva Neurosciences (NASDAQ:NERV) last issued its quarterly earnings results on Friday, August 7th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.05. On average, analysts expect Minerva Neurosciences to post ($0.73) EPS for the current fiscal year and ($0.42) EPS for the next fiscal year.

Minerva Neurosciences Stock Up 1.3%

Shares of NERV stock opened at $2.35 on Tuesday. Minerva Neurosciences has a 52 week low of $1.96 and a 52 week high of $8.80. The firm has a 50 day moving average of $3.44 and a 200-day moving average of $4.87.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the stock. Zacks Research upgraded shares of Minerva Neurosciences from a “strong sell” rating to a “hold” rating in a research report on Friday, October 9th. Jefferies Financial Group upgraded shares of Minerva Neurosciences from a “hold” rating to a “mixed” rating and raised their price target for the stock from $7.50 to $10.00 in a report on Friday, August 14th. Wall Street Zen cut shares of Minerva Neurosciences from a “hold” rating to a “sell” rating in a report on Saturday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Minerva Neurosciences in a research note on Monday, September 21st. One analyst has rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Minerva Neurosciences presently has a consensus rating of “Hold” and an average price target of $10.33.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc is a biopharmaceutical company focused on developing treatments for central nervous system disorders. The company’s research has centered on conditions with significant unmet medical needs, including schizophrenia, depression and other psychiatric or neurological diseases.

Minerva’s lead product candidate has been roluperidone, an investigational therapy designed to address the negative symptoms of schizophrenia, such as social withdrawal, reduced motivation and diminished emotional expression.